Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR ...
Let's talk about the popular Edwards Lifesciences Corporation ( NYSE:EW ). The company's shares saw significant share... Edwards Lifesciences (NYSE:EW) has had a rough week with its share price ...
Stifel upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said the upgrade is predicated on “now more credible TAVR growth re-acceleration ...